Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes
- Giammarino, Federica
- de Salazar, Adolfo
- Malet, Isabelle
- Viñuela, Laura
- Fuentes, Ana
- Saladini, Francesco
- Bartolini, Niccolò
- Charpentier, Charlotte
- Lambert-Niclot, Sidonie
- Sterrantino, Gaetana
- Colao, Maria Grazia
- Micheli, Valeria
- Bertoli, Ada
- Fabeni, Lavinia
- Teyssou, Elisa
- Delgado, Rafael
- Falces-Romero, Iker
- Aguilera, Antonio
- Gomes, Perpetua
- Paraskevis, Dimitrios
- Santoro, Maria M
- Ceccherini-Silberstein, Francesca
- Marcelin, Anne-Genevieve
- Moreno, Cristina
- Zazzi, Maurizio
- García, Federico
Department of Medical Biotechnologies, University of Siena, Siena, Italy
Clinical Microbiology, Hospital Universitario Clinico San Cecilio, Granada, Spain
Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
Clinical Microbiology, Hospital Universitario Clinico San Cecilio, Granada, Spain
Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Clinical Microbiology, Hospital Universitario Clinico San Cecilio, Granada, Spain
Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Department of Medical Biotechnologies, University of Siena, Siena, Italy
Department of Medical Biotechnologies, University of Siena, Siena, Italy
Service de Virologie, Université Paris Cité, INSERM, IAME, UMR 1137, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France
Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France
Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy
Laboratory of Microbiology and Virology, Careggi Hospital, Florence, Italy
Department of Clinical Microbiology, Virology, and Bioemergencies, Sacco University Hospital, Milan, Italy
Laboratory of Virology, University Hospital Tor Vergata, Rome, Italy
Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Virology and Biosafety Laboratories Unit, Lazzaro Spallanzani-IRCCS, National Institute for Infectious Diseases, Rome, Italy
Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
Clinical Microbiology Service, Instituto de Investigación, Hospital 12 de Octubre, Madrid, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Clinical Microbiology Service, Hospital La Paz, Madrid, Spain
Clinical Microbiology Service, Hospital Clínico Universitario de Santiago, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
Egas Moniz Center for Interdisciplinary Research, Egas Moniz School of Health and Science, Almada, Portugal
Laboratório de Biología Molecular, Centro Hospitalar Lisboa Ocidental-Hospital Egas Moniz, Lisboa, Portugal
Department of Hygiene, Epidemiology, and Medical Statistics, National and Kapodistrian University of Athens, Athens, Greece
Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain
Department of Medical Biotechnologies, University of Siena, Siena, Italy
Clinical Microbiology, Hospital Universitario Clinico San Cecilio, Granada, Spain
Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
F. G., A. d. S., and I. M. are joint first authors.
Correspondence: Federico García, PharmD, PhD, Hospital Universitario San Cecilio-Instituto Investigación Biosanitaria Ibs.Granada, Av. del Conocimiento S/N, 18016, Granada, Spain ([email protected]); Adolfo de Salazar, PharmD, PhD, Hospital Universitario San Cecilio-Instituto Investigación Biosanitaria Ibs.Granada, Av. del Conocimiento S/N, 18016, Granada Spain, [email protected].
Potential conflicts of interest. E. T. has received funds for attending meetings and/or travel from Moderna. C. C. has received funds for attending symposia, speaking, organizing educational activities, and travel grants from Gilead Sciences, ViiV Healthcare, and Merck Sharp and Dohme. A. A. has received funds for attending symposia, speaking, organizing educational activities, and travel grants from Gilead Sciences, Roche, Vircell, and Abbvie. R. D. has served as a speaker, a consultant, and an advisory board member for GSK, Gilead, Merck Sharp and Dohme, Hologic, and ViiV Healthcare. S. L.-N. has received funds for attending symposia, speaking, organizing educational activities, and travel grants from Gilead Sciences, Merck Sharp and Dohme, and ViiV Healthcare. P. G. has received funds for attending symposia, speaking, and travel grants from Gilead Sciences, Merck Sharp and Dohme, and ViiV Healthcare. D. P. has received funds for attending meetings and/or travel from Moderna. M. M. S. has received funds for attending symposia, speaking, and organizing educational activities from ViiV Healthcare, Janssen-Cilag, MSD, and Theratechnologies. F. C.-S. has received funds for attending symposia, speaking, organizing educational activities, travel grants, advisory/consulting, and/or research grants from Abbvie, Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, Theratechnologies, and ViiV Healthcare. A.-G. M. has received funds for attending symposia, speaking, and research grants from VIIV Healthcare, Gilead Sciences, and Merck Sharp and Dohme. M. Z. reports research grants from MSD, Theratechnologies, and ViiV Healthcare; consulting fees for advisory boards from MSD, Gilead Sciences, Theratechnologies, and ViiV Healthcare; support for attending meetings from Gilead Sciences and Theratechnologies; and receipt of drug for in vitro studies from Theratechnologies and MSD, outside the submitted work. F. G. has received funds for attending symposia, speaking, and research grants from Abbvie, Gilead, Merck/MSD, Roche, Hologic, Thera, Vircell, and Seegene. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Received October 25, 2023
Accepted January 10, 2024
Revised February 07, 2024
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
